CD22 and colon adenocarcinoma: In this work, we explore multiple effects on how SIGLECs co-evolve with COAD, in terms of expressions, prognostic behaviors, clinical trends, enrichment analysis, immune mechanisms, etc. We find SIGLEC family, especially SIGLEC-1,14,15 and CD22, are promising tracers for COAD, while SIGLEC-1,15 and CD22 are identified as hub genes.